MC
NAVB

Miles Capital’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Miles Capital’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-6,227
Closed -$330K – 124
2013
Q3 		$330K Sell
6,227
-480
-7% -$28K 0.19% 92
2013
Q2 		$358K Buy
+6,707
New +$335K 0.17% 97

Other funds holding NAVB

PM
Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nomura Holdings
Nomura Holdings Tokyo, Japan $37.7B AUM 34.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CA
Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Miles Capital's NAVB Position: Q4 2013 in Review

Miles Capital sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q4 2013, closing a stake of 6,227 shares — an estimated $330K sold.

Miles Capital first reported a position in NAVB in Q2 2013 and held it in 2 quarters. The position peaked at $358K in Q2 2013. 87 funds tracked by Wall St. Rank hold NAVB as of Q4 2013.

  • Miles Capital reported no remaining Navidea Biopharmaceuticals Inc. position as of Q4 2013 after selling out during the quarter.
  • Miles Capital sold 6,227 Navidea Biopharmaceuticals Inc. shares in Q4 2013, an estimated $330K.
  • Miles Capital first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 2 quarters.
  • Miles Capital's Navidea Biopharmaceuticals Inc. position peaked at $358K in Q2 2013.
  • 87 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q4 2013.

Based on Miles Capital's 13F filing for Q4 2013, filed 11 Feb 2014.